Skip to content
BHP

Peptides studied for pressure-sore healing research

Last reviewed:

Pressure-ulcer research peptides target the chronic inflammatory and microvascular dysfunction that characterise stage III and IV wounds, with GHK-Cu and LL-37 as the leading research candidates.

GHK-Cu has demonstrated the capacity to reactivate metabolically impaired, senescent fibroblasts in aged tissue models — a mechanism uniquely relevant to pressure ulcers, where senescent cells are a principal reason for healing failure.

— Notable finding

Condition background

Pressure ulcers (also termed pressure injuries or decubitus ulcers) are localised injuries to skin and underlying tissue resulting from sustained pressure, shear, or friction — commonly at bony prominences such as the sacrum, heel, ischial tuberosity, and greater trochanter. The European Pressure Ulcer Advisory Panel (EPUAP) classifies them in four stages, with stage III and IV representing full-thickness tissue loss extending to fascia, muscle, or bone. In the UK, pressure ulcers affect an estimated 700,000 people per year, with the majority developing in hospital or care-home settings among elderly, immobile, or critically ill patients. Pathophysiology involves sustained ischaemia-reperfusion injury to microvascular tissue, impairing oxygen and nutrient delivery; subsequent inflammation, neutrophil activation, and proteolytic tissue destruction; and a wound environment characterised by chronic high matrix metalloproteinase activity, elevated pro-inflammatory cytokines, and senescent fibroblasts that are unresponsive to growth-factor stimulation. These features — together with bacterial colonisation and biofilm — trap pressure ulcers in a non-healing, chronic inflammatory state.

Current treatment landscape

UK pressure ulcer management is guided by NICE Clinical Guideline NG89. Prevention — pressure relief, regular repositioning, specialised mattresses, nutritional support, and skin assessment — is the primary focus. Once established, management involves debridement (sharp, autolytic, enzymatic, or larval), wound-bed preparation, and appropriate dressing selection based on exudate level, infection, and tissue type. NPWT (negative-pressure wound therapy) is used for deeper wounds to manage exudate and promote granulation. Bacterial burden is managed with antimicrobial dressings (silver, iodine, PHMB) and systemic antibiotics when clinical infection is confirmed. Surgical debridement and reconstructive flap surgery may be required for stage IV wounds. The human and financial burden is significant — treating a single stage IV ulcer can cost £70,000 or more over the patient's care episode.

Why peptides are studied here

Pressure-ulcer models are characterised by the need to restore function to a wound environment where the normal healing cascade has stalled. [GHK-Cu](/peptides/ghk-cu) is the most extensively studied peptide in chronic-wound contexts: it reactivates fibroblasts from a senescent state, upregulates collagen synthesis and VEGF expression, activates anti-oxidant gene networks (SOD, catalase), and modulates MMP activity for controlled matrix remodelling. Its ability to 'reset' aged or metabolically impaired fibroblasts is particularly relevant to the senescent cell populations found in pressure ulcers. [LL-37](/peptides/ll-37) addresses the antimicrobial and immune-modulation dimensions — reducing biofilm bacterial burden while simultaneously promoting keratinocyte migration and angiogenesis. [BPC-157](/peptides/bpc-157) offers vascular repair through the VEGFR2 and NO pathways, addressing the microvascular insufficiency at the wound base. [Thymosin beta-4](/peptides/thymosin-beta-4) contributes cell-migratory and anti-inflammatory effects that may help transition the wound from the chronic inflammatory to the proliferative repair phase.

Relevant research peptides

Notable study findings

  • GHK-Cu

    GHK-Cu applied topically to full-thickness excisional wounds in aged rodents restored fibroblast responsiveness to growth factors, increased collagen deposition, and improved wound closure rate — findings mechanistically relevant to the senescent fibroblast populations characteristic of chronic pressure ulcers.

  • LL-37

    LL-37 demonstrated direct antibiofilm activity against Staphylococcus aureus and Pseudomonas aeruginosa wound isolates in vitro, and promoted keratinocyte migration and wound re-epithelialisation in murine excisional wound models, suggesting dual antimicrobial and pro-regenerative utility.

  • BPC-157

    BPC-157 restored microvascular flow and accelerated granulation tissue formation in ischaemia-reperfusion wound models, addressing the vascular insufficiency at the base of stage III and IV pressure ulcers where tissue perfusion is most critically compromised.

Relevant research stacks

UK regulatory notes

GHK-Cu, LL-37, BPC-157, and thymosin beta-4 are not licensed by the MHRA for pressure ulcer management or any other human indication in the UK. BPC-157 is WADA-listed under S0. The other peptides on this page are not currently on the WADA Prohibited List, but researchers should verify current status annually. This page is for laboratory research reference only.

Frequently asked questions

What distinguishes a chronic non-healing wound from an acute wound at the biological level?
Chronic wounds are characterised by persistent elevation of pro-inflammatory cytokines (TNF-α, IL-1β), chronically high matrix metalloproteinase activity that degrades growth factors and extracellular matrix faster than it is produced, and a predominance of senescent fibroblasts that no longer respond normally to growth-factor stimulation. They lack the orderly progression through inflammatory, proliferative, and remodelling phases that characterises acute wound healing.
Why is GHK-Cu particularly studied for chronic wound applications?
GHK-Cu appears to have a specific capacity to restore fibroblast function that has declined due to age or metabolic stress. It upregulates collagen synthesis, stimulates VEGF expression, activates anti-oxidant gene networks, and modulates MMP activity — addressing multiple aspects of the chronic wound environment simultaneously. Its naturally occurring status (it is found in human plasma, saliva, and urine) has historically made it an attractive cosmetic and wound-care research target.
How does LL-37 address both infection and healing deficits in pressure ulcers?
LL-37 is a dual-function cathelicidin peptide. Its cationic amphipathic structure disrupts bacterial membranes with broad-spectrum activity, including against biofilm-forming organisms common in pressure ulcers. Simultaneously, it acts on human cells to promote keratinocyte migration (via FPR2 receptor signalling), stimulate angiogenesis (via VEGF and FPRL1), and modulate macrophage polarisation towards a more pro-regenerative M2 phenotype.
What are the EPUAP pressure ulcer stages?
The European Pressure Ulcer Advisory Panel classifies pressure injuries across four stages: Stage I (non-blanchable erythema of intact skin), Stage II (partial-thickness skin loss with exposed dermis), Stage III (full-thickness skin loss with visible adipose tissue), and Stage IV (full-thickness tissue loss with exposed bone, tendon, or muscle). Deep-tissue injury and unstageable categories are additional classifications. Research peptide interest is greatest in stage III and IV wounds where healing biology is most significantly impaired.
Is negative-pressure wound therapy compatible with topical peptide research?
NPWT and topical peptide application target different aspects of wound management. NPWT removes excess exudate, reduces oedema, and promotes granulation tissue formation through mechanical stimulation. Topical peptides address cellular and matrix biology. In research settings, sequential application — peptide application between NPWT dressing changes — is mechanistically feasible, but no published combination studies of NPWT and the peptides described on this page have been identified in the literature.
What in-vitro models are used for pressure-ulcer peptide research?
Common in-vitro systems include scratch-assay migration studies using keratinocytes or fibroblasts, collagen gel contraction assays measuring fibroblast contractile function, cytokine profiling in LPS-stimulated macrophage cultures, and 3D skin equivalent models (full-thickness reconstructed skin). In-vivo models typically use full-thickness excisional wound models in rodents, sometimes combined with ischaemia-reperfusion to better mimic pressure injury pathophysiology.

Where to source research peptides for laboratory research

The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.

  • PeptideAuthority.co.uk

    UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.

  • PeptideBarn.co.uk

    Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.